ORENCIA 250 mg powder for concentrate for solution for infusion
Sponsors
University Of Minnesota, Dr Reddy's Laboratories Limited, Universitaetsklinikum Erlangen AöR, IRCCS Istituto Giannina Gaslini
Conditions
COVID-19Juvenile idiopathic arthritisPsoriatic arthritisRheumatoid Arthritis
Phase 3
A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
RecruitingCTIS2023-508251-39-00
Start: 2020-09-18Target: 370Updated: 2026-01-20
A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Immune Modulation Strategy Trial
CompletedCTIS2023-504487-41-00
Start: 2023-11-28End: 2025-08-11Target: 345Updated: 2025-05-09
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
CompletedCTIS2023-506664-14-00
Start: 2024-10-24End: 2025-12-02Target: 415Updated: 2025-11-11